3D printing in healthcare is the use of additive manufacturing to create medical objects layer by layer, from surgical planning models and custom implants to prosthetics and even experimental living tissue. The technology starts with a digital file, often derived from a patient’s own imaging scan, and builds a physical object by depositing successive layers of material until the final shape is complete. What makes it transformative for medicine is personalization: every product can be tailored to a single patient’s anatomy without retooling a factory line.
How a Patient’s Scan Becomes a 3D Print
The process typically follows three steps. First, a patient undergoes a CT or MRI scan, which produces a detailed volumetric image of their anatomy stored in a standard medical imaging format called DICOM. Second, a technician uses specialized software to isolate the relevant structure, whether that’s a bone, organ, or blood vessel, from everything surrounding it. This step, called segmentation, converts the scan data into a virtual 3D model. Third, that model is translated into instructions the printer can follow, and the physical object is printed.
This workflow means that every 3D printed medical product can reflect the exact dimensions, curves, and irregularities of a specific patient’s body. A surgeon preparing for a complex case isn’t working from a textbook diagram or a flat screen image. They’re holding a physical replica of the anatomy they’ll operate on.
Surgical Planning Models
One of the most established uses of 3D printing in medicine is creating patient-specific anatomical models that surgeons study and rehearse on before an operation. These replicas let surgical teams identify unexpected challenges, plan their approach, and communicate more clearly with patients about what to expect.
A study of patients undergoing robotic prostate surgery compared outcomes when surgeons used standard imaging alone versus imaging plus a 3D printed model of the patient’s anatomy. The group with 3D models saw positive surgical margins (meaning cancer cells found at the edge of removed tissue) drop from 22.2% to 8.1%. Operating time also fell by about nine minutes per case. Neither result reached statistical significance in this particular study, but the trend illustrates why hospitals are increasingly investing in on-site 3D printing labs: even modest improvements in precision and efficiency compound across thousands of surgeries.
Custom Implants
Titanium and its alloys have long been the preferred material for dental and orthopedic implants because of their strength, biocompatibility, and ability to bond directly with bone. 3D printing adds a critical advantage: the ability to build implants with open, porous surface structures that mimic the spongy interior architecture of natural bone. These micro-pores encourage bone cells to grow into and around the implant rather than simply sitting next to it.
In a pilot study of 3D printed titanium dental implants, researchers observed bone growing into the microporosities of the printed surface within 12 weeks. That kind of integration is difficult to achieve with traditionally machined implants, which tend to have smoother surfaces. For patients, better integration means a more stable implant and a lower risk of loosening over time. The same principle applies to larger orthopedic implants for hips, knees, and spinal fusion, where 3D printing allows surgeons to order implants shaped to fit a patient’s exact anatomy rather than choosing the closest available size from a catalog.
Prosthetics and Orthotics
3D printing has generated enormous excitement around affordable prosthetic limbs, particularly for children who outgrow devices quickly. The reality, at least for now, is more nuanced than the headlines suggest. A detailed cost comparison of 3D printed wrist orthoses versus conventional thermoplastic ones found that the 3D printed versions actually cost more per unit: roughly €47 compared to €30 for the traditional method. Material costs were dramatically lower for the 3D printed version (about €7 versus €21), but labor ate up the savings. The 3D printing workflow required about 45 minutes of active therapist time spread across two appointments, plus roughly 11 hours of printing, compared to just 15 minutes of hands-on work for a conventional orthosis made in a single session.
Where 3D printing holds a clear advantage is in design freedom. A printed orthosis can include ventilation holes, precise pressure distribution patterns, and an exact fit based on a surface scan of the patient’s limb. For patients who need devices with unusual geometries, or for pediatric patients whose anatomy doesn’t match standard sizing, the extra cost may be well worth it. As printing speeds increase and software automates more of the design process, that cost gap is expected to narrow.
3D Printed Medications
In 2015, the FDA approved SPRITAM, an epilepsy medication and the first 3D printed drug to reach the market. The pill is made using a powder-liquid layering process that produces a highly porous tablet. It dissolves in the mouth within seconds with just a sip of water, which is a significant benefit for patients who have difficulty swallowing traditional pills.
The larger promise of 3D printed pharmaceuticals goes beyond a single product. The technology allows pharmacists to potentially combine multiple drugs into one “polypill,” each layer programmed to release at a different rate. A patient taking three medications at three different times of day could instead take a single pill that handles the timing internally. Doses can be calibrated to the nanogram for drugs with a narrow therapeutic window, where small differences between an effective dose and a toxic one matter enormously. Even the shape, flavor, color, and texture of pills can be customized, which has shown potential for improving adherence in children. None of this is routine yet, but the flexibility of the platform makes personalized pharmacy a realistic near-term goal rather than a theoretical one.
Bioprinting Living Tissue
Bioprinting takes the concept further by using living cells, suspended in gel-like materials called bioinks, as the “raw material.” Printers deposit these cell-laden layers to build structures that can mature into functional tissue. Researchers have successfully printed relatively simple tissues including skin grafts, cartilage patches, and small blood vessels.
Printing a full, transplantable organ like a heart or liver remains far off. The challenge is not just size but complexity. A working organ requires multiple cell types arranged in precise spatial relationships, a network of blood vessels to supply nutrients, and the structural integrity to survive implantation. Current bioprinted structures struggle with all three. Biomaterials degrade unpredictably, tissue integration with the host body is inconsistent, and there’s no way to safety-test a custom organ before putting it in the patient it was made for. These aren’t small engineering problems to optimize away. They represent fundamental biological hurdles that will take years, possibly decades, to clear.
Regulatory Oversight
The FDA regulates 3D printed medical devices through the same pathways as traditionally manufactured ones, evaluating them for safety and effectiveness before they reach patients. Where things get complicated is point-of-care printing, the growing practice of hospitals producing devices on-site rather than ordering them from a manufacturer. When a hospital prints a surgical model or a custom cutting guide in its own lab, the traditional manufacturer-regulator-hospital chain breaks down.
The FDA has published a discussion paper exploring how to handle this shift, considering factors like the technical capabilities of hospital printing facilities, quality control processes, and which types of devices pose enough risk to require formal regulatory review. The agency is still gathering input from hospitals, device manufacturers, and clinicians, so the regulatory framework for point-of-care printing remains a work in progress. For now, hospitals operating 3D printing programs typically follow internal quality management systems modeled on manufacturing standards, but formal federal requirements specific to this setting have not been finalized.